A novel triptolide-nucleolin aptamer conjugate (TMPC001) with super antitumor activity on advanced pancreatic cancer

Liu, B; He, Xiaoman; Zhang, G; Lu, Axin

doi:10.1055/s-0034-1382359

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, a tissue distribution study indicated that NACC could selectively target tumor tissue and accumulation in liver and kidney tissues was decreased. The tissue distribution assay confirmed that nucleic acid aptamer modification could enhance anticancer activity and reduce liver toxicity (Liu, 2017).…”

Section: Direct Chemical Modification Delivery Systemmentioning

confidence: 78%

Recent advances in drug delivery of celastrol for enhancing efficiency and reducing the toxicity

Sun,

Wang,

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Celastrol is a quinone methyl triterpenoid monomeric ingredient extracted from the root of Tripterygium wilfordii. Celastrol shows potential pharmacological activities in various diseases, which include inflammatory, obesity, cancer, and bacterial diseases. However, the application prospect of celastrol is largely limited by its low bioavailability, poor water solubility, and undesired off-target cytotoxicity. To address these problems, a number of drug delivery methods and technologies have been reported to enhance the efficiency and reduce the toxicity of celastrol. We classified the current drug delivery technologies into two parts. The direct chemical modification includes nucleic acid aptamer–celastrol conjugate, nucleic acid aptamer–dendrimer–celastrol conjugate, and glucolipid–celastrol conjugate. The indirect modification includes dendrimers, polymers, albumins, and vesicular carriers. The current technologies can covalently bond or encapsulate celastrol, which improves its selectivity. Here, we present a review that focalizes the recent advances of drug delivery strategies in enhancing the efficiency and reducing the toxicity of celastrol.

show abstract

Section: Direct Chemical Modification Delivery Systemmentioning

confidence: 78%

Recent advances in drug delivery of celastrol for enhancing efficiency and reducing the toxicity

Sun,

Wang,

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…In addition, SKOV-3 cells were more sensitive to compound (20) than other tested cancer lines, which showed a 7-fold increase in tumor sensitivity to nontumor fibroblast cell lines. Liu (2017 ) innovatively linked the nucleoside aptamer to C-20 through celastrol to synthesize compound (21). Through in vitro cytotoxicity experiments on PANC-1 and normal human liver cell line, it was proved that compound (21) has higher anti-proliferative and growth activities, has less liver toxicity and high selectivity compared with celastrol.…”

Section: Introductionmentioning

confidence: 99%

Celastrol: A Review of Useful Strategies Overcoming its Limitation in Anticancer Application

Shi

et al. 2020

Front. Pharmacol.

117

View full text Add to dashboard Cite

Celastrol, a natural bioactive ingredient derived from Tripterygium wilfordii Hook F, exhibits significant broad-spectrum anticancer activities for the treatment of a variety of cancers including liver cancer, breast cancer, prostate tumor, multiple myeloma, glioma, etc. However, the poor water stability, low bioavailability, narrow therapeutic window, and undesired side effects greatly limit its clinical application. To address this issue, some strategies were employed to improve the anticancer efficacy and reduce the side-effects of celastrol. The present review comprehensively focuses on the various challenges associated with the anticancer efficiency and drug delivery of celastrol, and the useful approaches including combination therapy, structural derivatives and nano/micro-systems development. The specific advantages for the use of celastrol mediated by these strategies are presented. Moreover, the challenges and future research directions are also discussed. Based on this review, it would provide a reference to develop a natural anticancer compound for cancer treatment.

show abstract

A novel triptolide-nucleolin aptamer conjugate (TMPC001) with super antitumor activity on advanced pancreatic cancer

Cited by 2 publications

References 0 publications

Recent advances in drug delivery of celastrol for enhancing efficiency and reducing the toxicity

Recent advances in drug delivery of celastrol for enhancing efficiency and reducing the toxicity

Celastrol: A Review of Useful Strategies Overcoming its Limitation in Anticancer Application

Contact Info

Product

Resources

About